Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Progression inevitably happens after 10–14 months of first- or second-generation EGFR TKIs treatment for acq...

Full description

Saved in:
Bibliographic Details
Published in:Front Oncol
Main Authors: Wu, Leilei, Ke, Linping, Zhang, Zhenshan, Yu, Jinming, Meng, Xue
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7775519/
https://ncbi.nlm.nih.gov/pubmed/33392095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.602762
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items